# Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

> **NCT05908682** · — · RECRUITING · sponsor: **Scynexis, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Vulvovaginal Candidiasis
- Candida Infection
- Vaginal Candidiasis

## Interventions

- **OTHER:** Non-interventional study

## Key facts

- **NCT ID:** NCT05908682
- **Lead sponsor:** Scynexis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-28
- **Primary completion:** 2029-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05908682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05908682, "Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05908682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*